Market Overview

UPDATE: Stifel Reiterates On HealthSouth As Second Quarter Easily Exceeds Projection

Share:
Related HLS
Benzinga's Top Upgrades, Downgrades For February 14, 2017
Companies That Have The Most To Lose If Obamacare Is Repealed
Tracking Larry Robbins' Glenview Capital Management Portfolio - Q4 2016 Update (Seeking Alpha)

In a report published Tuesday, Stifel analyst Robert Mains reiterated a Buy rating on HealthSouth (NYSE: HLS), and raised the price target from $38.00 to $41.00.

In the report, Stifel noted, “HealthSouth reported second quarter earnings well ahead of our estimate. The company reported income from continuing operations per share (its EPS proxy) of $0.81, beating our $0.65 estimate. Excluding an accounting gain, income from continuing operations per share were $0.54 compared to our at-consensus $0.48 estimate. We are raising our earnings estimate and target price, as the company also increased its guidance.”

HealthSouth closed on Monday at $37.64.

Latest Ratings for HLS

DateFirmActionFromTo
Feb 2017Craig-HallumInitiates Coverage OnBuy
Feb 2017Craig-HallumInitiates Coverage OnBuy
Jan 2017PiperJaffrayInitiates Coverage OnNeutral

View More Analyst Ratings for HLS
View the Latest Analyst Ratings

Posted-In: Robert Mains StifelAnalyst Color Price Target Analyst Ratings

 

Related Articles (HLS)

View Comments and Join the Discussion!